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Abstract:  
 
Introduction: Acute pancreatitis remains the most common severe complication of 
endoscopic retrograde cholangiopancreatography (ERCP). The exact cause of post-
ERCP pancreatitis (PEP) is unclear. Regardless of the mechanism that initiates PEP, the 
pathways of inflammation are similar to other forms of acute pancreatitis and include the 
activation of various inflammatory cytokines, released from the acinar cells and 
subsequently from helper T lymphocytes and macrophages. Liver transplants (LTx) 
patients on immunosuppressive medications have impaired T-cell response and hence 
decreased ability to generate these cytokines. The aim of this study was to review 
incidence rates and risk factors of PEP in this LTx subset of patient population compared 
to non transplant (non-LTx) patients.    
 
Methods: Retrospective review of liver transplant database from January 2005 to 
September 2015 was performed. Liver transplant patients who underwent ERCP in the 
post-transplant period as part of their usual management were included in the study and 
compared with non-LTX patients who underwent ERCP. The study was approved by IRB. 
Electronic medical records were reviewed for any mention of pancreatic-type pain and 
pancreatic enzyme testing, if any after the ERCP. Diagnosis of Post-ERCP pancreatitis 
was made on the basis of both clinical and laboratory results as per standard definitions 
of PEP.   
 
Results: During this period, 109 LTx patients underwent 235 ERCP procedures. The data 
was compared with 348 non-transplant patients (not on any immunosuppression) who 
underwent total of 536 ERCP procedures. PEP developed in 24 (4.47%) cases in the non-
LTx group as compared to 4 (1.7%) cases in the LTx group (p = 0.061, OR 2.70). History 
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of LTx showed trend towards decrease in risk of PEP on univariate analysis (OR 0.36, p 
= 0.068, 95% CI = 0.12 - 1.07). However, on multivariate analysis only female gender (OR 
2.35, P < 0.038, CI 1.04 - 5.28), history of PEP (OR 5.77, P < 0.001, CI 2.01 - 16.55) and 
pancreatic duct contrast injection (OR 6.20, P < 0.001 CI 2.75 - 13.97) were significantly 
associated with risk of PEP. Also the severity of pancreatitis was mild in all 4 LTx patients 
as compared to 21 out of 24 patients (87%) with mild PEP in the non-LTx group (p <0.001).   
 
Conclusion: The risk of PEP in liver transplant patients on immunosuppression appears 
lower than the historical risk. Inhibition of the inflammatory transcriptional factors such as 
NF-B and NFAT by the calcineurin inhibitors may be a potential explanation. Further 
studies are needed targeting calcineurin activation as a therapeutic approach in 
prevention of PEP.  
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Introduction: 
Biliary tract complications  occur in 5% to 25% of patients after liver 
transplantation.(1-4)  These complications include biliary strictures, bile leaks, 
choledocholithiasis, biliary casts, biloma, and hemobilia. Bile duct anastomotic strictures 
are quite common and affect 15% to 20% of patients after deceased OLT and 19% to 40% 
after living donor liver transplantation.(5) ERCP is the preferred initial treatment choice 
because it helps to confirm the diagnosis and allows therapy.(6-9) The reported 
complication rates for ERCP in the general population vary between 4% and 12% (10-14)  
though the most frequent and feared complication of ERCP is post-ERCP pancreatitis 
(PEP), which is associated with significant post procedure morbidity and mortality. The 
incidence of PEP reported in the literature ranges from 1% to 30% of all procedures, the 
frequency depending on different patient and procedure related variables. Rates of 
pancreatitis of 2% to 9% are typical of most unselected prospective series.(15) Published 
series of LTx recipients who underwent ERCP for biliary complications indicate that the 
risks of bleeding, pancreatitis, and cholangitis, among other complications, after the 
procedure range between 2% and 18%.(16-19) Nonetheless, the specific risks of PEP in 
LTx recipients have not been well studied, and there are limited data on the complications 
of this procedure in this patient population.   Although procedure-related factors play a role 
in the development of these complications, patient-related factors likely play a relevant 
role in this population, given the fact that LTx recipients receive long-term 
immunosuppression. In addition, prior studies did not specifically evaluate the procedure 
related risk factors for PEP in this patient population. These patients are on long-term 
immunosuppression and the effects of these medications on PEP rates are unknown. 
PEP, being an immune mediated inflammatory process, and LTx patients are on 
immunosuppression, we hypothesize the risk of PEP in this LTx population is 
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different than the risk in general population. The purpose of this study was to examine 
the incidence, specific risk factors of PEP complications in LTx patients. Secondary aim 
was to determine the severity of PEP in LTx patients.  
Material and methods:  
This study was conducted at University of Nebraska Medical Center. The 
institutional review board approved the study protocol. Retrospective review of liver 
transplant database from January 2005 to September 2015 was performed. Adult liver 
transplant patients who underwent ERCP in the post-transplant period as part of their 
usual management were included in the study. The patients were identified by searching 
the transplant database using procedure codes for ERCP. The Medical records of selected 
patients were retrospectively reviewed and both patient and procedure related potential 
variables were collected. The procedures were performed by the university academic 
faculty. Management of the ERCP findings i.e. choice of biliary stents for findings of 
anastomotic stricture or bile leak was as per the discretion of the endoscopist. Difficult 
biliary cannulation was recorded as per the description in the procedure report i.e. multiple 
attempts to cannulate CBD or pre-cut sphincterotomy done. Antibiotics were given to 
patients with evidence of infection or if complete biliary drainage could not be attained. 
Pharmacological prophylaxis with rectal indomethacin and/or pancreatic stent placement 
for PEP prophylaxis was performed as per the discretion of the endoscopist. At our 
institution, sedation for the ERCP is provided by anesthesiologist and patients are 
routinely discharged after the procedure unless clinical situation dictates otherwise. To 
identify the development of PEP, the electronic medical records were reviewed for any 
mention of pancreatic-type pain and pancreatic enzyme testing, if any within 3 days of the 
procedure date. Data regarding the indication for ERCP, patient related factors like age 
and gender, prior history of PEP and therapeutic procedures during ERCP such as 
3 
 
sphincterotomy, precut sphincterotomy, difficult cannulation, biliary stricture dilation, 
biliary stent placement, stone extraction, PD cannulation and PD stenting were evaluated 
and collected in database.  
Definition of findings  
 
Post ERCP pancreatitis (outcome variable): The diagnosis of PEP was made when 
there was documentation in the electronic record of at least 2 of 3 diagnostic criteria 
(typical pancreatic abdominal pain, elevated amylase and/or lipase levels, and pancreatic 
inflammation on cross-sectional imaging) were present within 72 hours of the ERCP 
procedure. The severity of PEP was defined according to criteria previously established 
by Cotton et al.(20) The severity was based mainly on the need for hospitalization. Mild 
events were considered when hospitalization was prolonged by 2 to 3 days, moderate by 
4 to 10 days, and severe by more than 10 days. Fatal events were considered when death 
was attributable to the procedure. Difficult cannulation: This was recorded as described 
per the endoscopist report, needed pancreatic duct (PD) stent placement to gain biliary 
access or via precut cannulation. Immunosuppression protocol: Standard 
immunosuppression in our center includes administration of tacrolimus or cyclosporine 
and prednisone. The dose of immunosuppression was managed by our institute transplant 
team as per the clinical protocol.  
 
Statistical analysis 
 
Sample size: Sample size was calculated a priori using an =0.05 (Type I error) and 
=0.2 (Type II error). The incidence of post-ERCP pancreatitis in general population was 
assumed at 8% and in post LTx  population was assumed to be about 2.5% based on 
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previous literature. This yielded a sample size of 514. Some patients had more than one 
ERCP procedure, however, the procedure and its complications were considered as 
independent observations for data analysis. Continuous variables were summarized as 
means and standard deviations or medians and range. Categorical variables were 
compared by using the χ2 or the Fisher exact test when appropriate. Continuous variables 
were compared by using the Student 2-tailed t test. The established risk factors for PEP 
were evaluated in univariate analysis.  Risk factors for PEP with P<0.15 in univariate 
analysis were evaluated with multivariate logistic regression techniques using backward 
stepwise elimination approach. Multivariate logistic regression analysis determined those 
variables independently associated with PEP, after adjusting for other variables. 
Associations are specified as odds ratio (OR) with a 95% confidence interval. A 2-sided 
probability value <0.05 was considered to be significant. Statistical analysis was 
performed by using SAS 9.4.    
 
Results  
 
From January 2005 to September 2015, a total of 235 ERCP procedures were 
performed on 109 LTx patients and 536 procedures performed in 348 non-LTx patients. 
Characteristics of ERCP procedure between the 2 groups is shown in table 1. In the LTx 
group, the mean age of patients was 52.73 years (74 males and 35 females). Indications 
of ERCP procedure in the LTx patients were:  abnormal LFT’s = 110, bile leak = 44, 
anastomotic stricture = 27, stent removal = 52, pancreatic fistula = 1, choledocholithiasis 
= 1. In the non-LTx  group there were 536 ERCP procedures performed (348 patients, 175 
males and 173 females), mean age was 55.68 years, more than the mean age in LTX 
group (P = 0.004). Indications of ERCP in the non-LTx group: bile duct stone = 53, bile 
leak = 31. Pancreatic duct leak 15, bile duct stricture = 8, abdominal pain = 39, chronic 
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pancreatitis = 72, abnormal abdominal imaging 17, abnormal liver tests = 163, acute 
pancreatitis  = 43, ampullary mass = 7, cholangitis = 16, cholangiocarcinoma = 9, stent 
follow up = 22, others = 41.  
Procedure related factors which are known to increase the risk of PEP were 
reviewed. Among them, biliary pre-cut sphincterotomy, CBD pneumatic dilation and 
difficult cannulation were not significantly different between the two groups. However, 
other high risk factors for PEP such as biliary sphincterotomy (p = 0.0002), pancreatic duct 
cannulation (p = 0.0001), pancreatic duct contrast injection (p = 0.012), pancreatic 
sphincterotomy (p < 0.0001) were more in non-LTx group. Intervention such as pancreatic 
duct stent placement, known to be protective for PEP were performed more in the non-
LTx group (p < 0.0001). In the non-LTx group, there were more patients with prior history 
of PEP (30 compared to 1 instance of PEP in the LTx group, p = 0.0002).   
Characteristics of patients who developed PEP are shown in table 2.  PEP 
developed in 24 (4.47%) cases in the non-LTx group as compared to 4 (1.7%) cases in 
the LTx group (p = 0.061, OR 2.70). Procedure related factors for increased risk of PEP 
(biliary sphincterotomy, pancreatic duct cannulation, pancreatic duct contrast injection, 
pancreatic sphincterotomy) were not statistically different between the two groups who 
developed PEP. Procedure related factor known to be protective for PEP i.e. pancreatic 
duct stent placement was performed in 13 patients in the non-LTx group as compared to 
none in the LTx group.  Patient related factors such as age and gender were similar in 
both groups. The only different patient related factor is use of immunosuppression 
medications in the transplant group. Also the severity of pancreatitis was mild 87% in non-
LTx group vs 100% in the transplant group assessed as per criteria of Cotton classification 
(p = 0.0017).  
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Univariate and multivariate logistic regression analyses were performed for the 
outcome of PEP among all patients. The univariate analysis (Table 3) showed an 
increased risk of PEP in cases where pancreatic interventions occurred such as PD 
stenting, pancreatic sphincterotomy, pancreatic duct contrast injections and PD 
cannulation. PEP was also significantly more in patients with prior history of PEP (OR 7.8, 
95% CI = 2.91 - 20.98). Among patients with LTx, the risk of PEP was lower but not 
statistically significant (OR 0.36, p = 0.068, 95% CI = 0.12 - 1.07). Multivariate logistic 
regression (Table 4) was performed after including only those variables in the analysis 
those had p<0.15 on univariate regression and then using a backward stepwise 
elimination approach to find the model that was the best fit. On multivariate analysis, 
female gender, prior history of PEP and only PD contrast injection were significantly 
associated with risk of PEP.  
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Discussion: Acute pancreatitis is the most common complication of ERCP, a procedure 
performed for various pancreato-biliary disorders. About 700,000 ERCP procedures are 
performed annually in the United States. With its inherent complication risk, PEP 
represents a substantial cause of morbidity and mortality. The causes of the initiating 
events of PEP during ERCP are not well understood. Some of the proposed causes 
include: mechanical obstruction of the papilla/pancreatic duct by edema/injury due to 
instrumentation, thermal injury from electrocautery, hydrostatic injury from the injection of 
contrast, or chemical or allergic injury from contrast injection. Regardless of the inciting 
cause of acute pancreatitis, the initial events occur at the level of acinar cells and one of 
the earliest event is rise in cytosolic calcium leading to activation of several signaling 
pathways. One of the targets of pathologic calcium rise is the Ca2+/calmodulin dependent 
serine/threonine phosphatase calcineurin. It is well established that the calcineurin-
dependent transcription factor, nuclear factor of activated T cells (NFATc) regulates 
trypsinogen activation, inflammation, and pancreatic tissue damage in AP.(21) In this 
study, they demonstrated that the activation of trypsinogen by secretagogues in acinar 
cells was prevented by pharmacologic inhibition of NFAT. Importantly, only calcineurin is 
known to activate the NFAT transcription factors thereby controlling the expression of 
several genes (e.g. genes for cytokines such as IL-2, IL-4 and IFNγ). FK-506, a calcineurin 
inhibitor has been shown to impair protease activation in pancreatic acinar cells and 
protects against mild pancreatitis in vivo.(22, 23) In addition to its ability to inhibit NFAT 
activation, FK-506 can also inhibit the NF-B pathway by blocking translocation of c-Rel 
from the cytoplasm to the nucleus, inhibit IL-2 production at the transcriptional level and 
decrease the local and systemic severity in acute pancreatitis.(21, 24, 25) In our 
preliminary studies we have also demonstrated protective effect of FK-506 in acute 
experimental pancreatitis. There was significant difference in histology scores and 
cytokine profile of animals treated with FK-506 prior to induction of pancreatitis as 
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compared to control animals (Figure 2 and 3). On similar lines, there was decreased 
production of pro-inflammatory cytokines (α-TNF, IL-1, IL-6) and increase in anti-
inflammatory IL-10 in animals treated with FK-506 (Figure 4). In addition, clinically, there 
are reports of decreased incidence of PEP in patients who are taking FK-506 for organ 
transplantation.(18, 26) FK-506 is routinely used in clinical practice for 
immunosuppression after liver transplantation and has favorable clinical profile.  
The results of this analysis specifically looked at risk of PEP in liver transplant 
recipients on immunosuppression. The findings in this study show that in LTx patients the 
frequency of PEP is 1.7%, lower than the non-LTx group (P = 0.068). The risk of PEP in 
our non-Tx group of 4.47% is comparable to reported rates of 4-12% in the general non-
LTx population. In our non-LTx cohort, there were significantly more procedure related risk 
factors for PEP such as biliary sphincterotomy, pancreatic duct cannulation, contrast 
injection and pancreatic sphincterotomy. 1.7% risk of PEP among LTx patients in our study 
is similar to results of our recent meta-analysis of risk of PEP among LTx patients (abstract 
ID: 343432, ACG 2017). Among 61 studies of ERCP in LTx patients, there were 7,730 
ERCP procedures performed on 3,980 patients, with 183 instances of PEP. The overall 
percentage of procedures with PEP, as estimated from our meta-analysis is 1.53% (95% 
CI: 0.90% - 2.28%). Forest plot (Fig. 1) shows all the studies included in our meta-analysis 
with number of ERCP procedures and incidence of PEP. The results of the meta-analysis 
and this current study indicate that the risk of PEP in LTx patients appear to be lower than 
the risk in general population.   
An important finding of our study is that, among the procedure related risk factors 
of PEP, only pancreatic duct contrast injection was significantly associated with PEP after 
adjusting for other variables. This is in line with recent mechanistic evidence of pancreatitis 
being induced by the radiocontast dye, which is used in ERCP. Sohail et al(27) have 
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demonstrated that incubation of mouse and human acinar cells with the radiocontrast dye 
(iohexol) led to increase in cytoplasmic calcium, activation of the transcription factors NF-
kB and nuclear factor of activated T cells. Suppressing Calcium signaling or calcineurin 
with FK506 prevented activation of NFkB and acinar cell injury. They also showed that 
calcineurin deficient mice were protected against induction of pancreatic inflammation by 
the radiocontrast dye. This is consistent with clinical data that show that risk of PEP can 
be decreased by pancreatic duct stenting to relieve ductal pressure, as well as by minimal 
contrast injection.(28, 29) However, placing pancreatic duct stent can be technically 
challenging in general practice and often is unsuccessful.   
The study has a few limitations. Being retrospective review, there may be 
inconsistencies in the description of the procedure findings and reporting. As an example 
number of biliary sphincterotomies, 261 in 348 non-LTx  patients  and 80 in 109 in LTx 
group appear lower than would be expected. Procedure related predictor variables such 
as difficult cannulation and amount of pancreatic duct contrast injection are not 
standardized. It is possible that some patients may have been admitted to outside 
hospitals for PEP and the complication was not recorded in their medical record here at 
our institution. The relationship between risk factor of pancreatic duct contrast injection 
and PEP may be affected since there is lack of accurate description about amount of 
pancreatic duct contrast injection leading to acinarization or not. Another limitation is about 
the exact immunosuppression regimen of the transplant patients, serum levels of FK-506 
were not available. FK-506 is the standard immunosuppression regimen and majority of 
the patients were on it. However, we were unable to obtain exact medications, with or 
without steroids and/or concomitant sirolimus at the time of the procedure. The role of 
steroids in prevention of PEP is controversial with studies reporting favorable effect(30) 
and no benefit.(31) The effect of steroids in pancreatitis is certainly plausible due to it 
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mechanistic properties, for example the inhibition of phospholipase A2, causing increase 
functional C1 esterase inhibitor levels. C1 esterase inhibitor is a protease known to 
suppress trypsin activation, a key process in acute pancreatitis. The effect if any of rectal 
indomethacin could not be reviewed in our study. Majority of procedures were performed 
before the widespread use of rectal indomethacin and its use is left to the discretion of the 
endoscopist. In the seminal study which showed benefit, in high risk patients rectal 
indomethacin along with pancreatic duct stenting reduced the risk of PEP from 16.1% to 
9.7% (P = 0.04).(32) In addition, in a randomized controlled study of consecutive patients 
undergoing ERCP, rectal indomethacin did not prevent post-ERCP pancreatitis.(33)  
Conclusions: Several signaling pathways are simultaneously activated in AP. Attempts 
at pharmco-prevention of PEP targeting single pathway have been largely unsuccessful, 
owing largely due to “compensation” and redundancy in immune response. Identifying and 
targeting the “initiating event” in acute pancreatitis may be more beneficial rather than 
preventing “inflammation” once it has been started. Mechanistically, rise of intracellular 
calcium in acute pancreatitis is accepted as the first event after the injurious stimuli and 
Ca2+/calmodulin-dependent phosphatase calcineurin has been shown to be an important 
target of this pathologic rise in acinar cell calcium. Our study provides some clinical data 
suggesting that use of calcineurin inhibitors may retard calcium mediated processes and 
thus prevent PEP. Further studies are needed to investigate its mechanism and efficacy 
in prevention of PEP.  
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Table 1: Baseline characteristics of ERCP procedure of participants  
No of procedures 
Non-LTx 
(n=536) 
LTx (n =235) P value 
Age (yrs) 55.68 52.73 0.004 
Gender 
Male 278 Male 156 0.001 
Female 258 Female 79  
History of Post-ERCP 
Pancreatitis 
30 1 0.001 
Therapeutic intervention at 
each ERCP, no (%) 
  
 
 
Biliary Sphincterotomy 261 80 0.001 
Biliary Precut 
Sphincterotomy 
14 8 0.638 
CBD pneumatic dilation 48 23 0.696 
Biliary stent placement 189 140 0.001 
Difficult Cannulation 68 35 0.421 
Pancreatic duct 
cannulation 
181 47 0.001 
Pancreatic duct contrast 
Injection 
138 41 0.012 
Pancreatic stent placement 121 16 0.001 
Pancreatic sphincterotomy 52 0 0.001 
Unsuccessful procedure 21 7 0.676 
Post-ERCP pancreatitis 24 (4.47%) 4 (1.70) 0.061 
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Table 2: Characteristics of patients who developed PEP  
 
Non-LTx group 
(24) 
LTx group (4) p-value 
Age (yrs) 52.4  48 0.681 
Gender 
Male 8 Male 3  
Female 16 Female 1 0.269 
History of PEP 6 1 1 
Biliary Sphincterotomy 13 1 0.595 
Biliary Precut 
Sphincterotomy 
0 0 1 
CBD pneumatic dilation 1 0 1 
Biliary stent placement 6 3 0.084 
Difficult Cannulation 4 2 0.191  
Pancreatic duct 
cannulation 
18 2 0.554 
PD contrast Injection 16 2 0.601 
Pancreatic stent 
placement 
13 0 0.101 
Pancreatic 
sphincterotomy  
7 0 0.545 
Severity of Pancreatitis 
21 mild, 3 
moderate 
4 mild  0.001 
  
Immunosuppression  0 4  0.001 
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Table 3: Univariate analysis for the risk of PEP  
 Odds ratio P value [95% Conf. Interval] 
Liver Transplant   0.36             0.068        0.12 - 1.07 
PD stent           4.32             0.001       2.00 - 9.31 
PD sphincterotomy 5.17             0.001       2.08 - 12.80        
PD injection       6.50             0.001        2.94 - 14.37 
PD entered         6.43             0.001      2.78 - 14.82 
Amp Balloon Dilation 0.35             0.314        0.04 - 2.66         
CBD Stent          0.62             0.250        0.27 - 1.39        
CBD sphincterotomy 1.27             0.532        0.59 - 2.70 
Difficult cannulation         2.24             0.072        0.93 - 5.42 
History of PEP     7.82             0.001        2.91 - 20.98         
Gender (females) 2.04             0.070        0.94 - 4.42        
Age group*         0.41             0.038        0.18 - 0.95        
*age group: <=56 or >56 (56 years is the median) 
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Table 4: Multivariate logistic regression for risk of PEP       
 Odds ratio P value [95% Conf. Interval] 
PD injection    5.77 0.001 2.75 - 13.97 
History of PEP 5.77 0.001 2.01 - 16.55 
Gender (F)      2.35 0.038 1.04 - 5.28 
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Figure 1: Studies of ERCP performed in LTx patients and risk of PEP   
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Figure 2: H&E staining of control pancreatitis with tissue 
edema and neutrophil infiltration 
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Figure 3: H&E stain of pancreas showing less edema 
and less infiltration with FK-506 therapy  
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Figure 4: Cytokine profile with FK-506 intervention 
experimental pancreatitis  
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